Bliss GVS Deal Takes Anupam Rasayan into Finished Medicines
Anupam Rasayan completes Bliss GVS Pharma acquisition, expands into finished medicines
Anupam Rasayan India Limited has completed the acquisition of a 48.2% controlling stake in Bliss GVS Pharma Limited at ₹299 per share, adding a finished medicines business to its speciality chemicals operations.
The transaction was completed through Mates Visa Consultancy, a wholly owned subsidiary of Anupam Rasayan. The two companies had signed the definitive agreement on May 23, 2026, followed by the mandatory open offer process required under securities regulations. SEBI records show the takeover process began with the public announcement on May 23 and continued through the detailed public statement and letter of offer.
For Anupam Rasayan, the deal changes the shape of its pharmaceutical business. The Surat-based company has traditionally worked in custom synthesis, speciality chemicals and pharmaceutical intermediates. Bliss GVS adds branded finished formulations, giving the group a business further along the medicine supply chain.
The acquisition has been funded through a ₹300 crore term loan and about ₹1,450 crore raised through non-controlling, non-voting instruments from financial investors led by Bain Capital, with Trust Group and Investec also participating. The combined funding is about ₹1,750 crore.
Bliss GVS Pharma was founded in 1984. It has more than 150 brands covering areas such as anti-malarial, anti-fungal, anti-bacterial, anti-inflammatory, anti-diabetic and cardiovascular medicines.
The company has manufacturing facilities in Maharashtra. Its facilities have approvals and certifications covering markets and regulators including the US Food and Drug Administration, EU-GMP and WHO-GMP. Bliss GVS also has a long-established business in suppositories and pessaries, dosage forms in which it has built a presence in international markets. Its own current company information lists products being supplied to more than 60 countries.
One number will draw attention from the industry: the manufacturing network is currently running at about 30% capacity utilisation. That leaves substantial unused production capacity, although turning that capacity into additional sales will depend on demand, product approvals, customers and execution.
Anand Desai, Managing Director of Anupam Rasayan India Ltd., said:
“We are pleased to announce the successful completion of the acquisition of Bliss GVS Pharma. This transaction marks an important milestone in our long-term strategy to build a diversified, integrated and innovation-led global pharmaceutical platform.
The acquisition strengthens our presence in finished pharmaceutical formulations and complements Anupam Rasayan’s expertise in key starting materials, intermediates and specialty chemicals. Combining our manufacturing and process chemistry capabilities with Bliss GVS Pharma’s formulation expertise, customer relationships, and market presence, we are well positioned to pursue forward integration, new product development, and geographic expansion.
We believe this integration will strengthen our capabilities, unlock meaningful operational and commercial synergies, and support sustainable, long-term value creation for all our stakeholders.”
The Bliss GVS transaction is the third major acquisition in Anupam Rasayan’s recent expansion programme.
The first came in 2022, when the company bought 24.96% of Tanfac Industries Limited and obtained joint management control with Tamil Nadu Industrial Development Corporation Limited. Anupam Rasayan later acquired another 0.83% through the open offer, taking its holding to about 25.8%. Tanfac is a speciality fluorides manufacturer and gives Anupam Rasayan access to products such as hydrofluoric acid and potassium fluoride.
The second move took the company outside India. In February 2026, Anupam Rasayan completed the purchase of 100% of Jayhawk Fine Chemicals Corporation in Galena, Kansas. The transaction had a purchase consideration of about US$150 million and an enterprise value of about US$134 million after taking Jayhawk’s cash position into account. Jayhawk brought a US manufacturing base and exposure to performance materials used in areas including electronics, energy, aerospace and polymers.
The Bliss GVS deal takes the group in another direction, towards finished pharmaceutical formulations.
If the four businesses are viewed together, Anupam Rasayan’s pro-forma revenue is expected to cross ₹4,000 crore, with estimated EBITDA of about ₹834 crore. The stated revenue contribution is ₹1,676 crore from Anupam Rasayan standalone, ₹711 crore from Tanfac Industries, ₹722 crore from Jayhawk Fine Chemicals and ₹927 crore from Bliss GVS Pharma.
The figures are pro-forma numbers rather than reported consolidated results from a single period. Their importance lies in showing the size of the business Anupam Rasayan is seeking to build after bringing the four operations together.
The company has also said the Bliss GVS acquisition was made at about 24 times its last-twelve-month earnings. That valuation needs to be viewed alongside the company’s current earnings, the available manufacturing capacity at Bliss GVS and the cost of bringing the businesses together.
The acquisition therefore gives Anupam Rasayan exposure at several stages of the chemical and pharmaceutical supply chain: raw materials through Tanfac, speciality chemicals and US manufacturing through Jayhawk, and finished medicines through Bliss GVS
The next test will be financial and operational. The businesses now have to work under one larger corporate structure, while Anupam Rasayan seeks to increase the use of Bliss GVS’s manufacturing capacity and expand the contribution from its pharmaceutical products.
Must Read:
Medical Expo 2026 to Bring the Healthcare Industry to Ahmedabad
Sun Pharma Gets Lerodalcibep Rights Outside the US and China